Dermavant Sci Drug Patent Portfolio

Dermavant Sci owns 1 orange book drug protected by 9 US patents Given below is the list of Dermavant Sci's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11590088 Use of Tapinarof for the treatment of chronic plaque psoriasis 13 Nov, 2039
Active
US10647649 Process for preparing tapinarof 13 Nov, 2038
Active
US11597692 Process for preparing tapinarof 13 Nov, 2038
Active
US10195160 Topical pharmaceutical compositions 19 May, 2036
Active
US10426743 Topical pharmaceutical compositions 19 May, 2036
Active
US11458108 Topical pharmaceutical compositions 19 May, 2036
Active
US11612573 Topical pharmaceutical compositions 19 May, 2036
Active
US11617724 Topical pharmaceutical compositions 19 May, 2036
Active
US11622945 Topical pharmaceutical compositions 19 May, 2036
Active


Given below is the list of recent legal activities going on the following drug patents of Dermavant Sci.

Activity Date Patent Number
Patent litigations
Petition Requesting Trial 13 May, 2024 US11590088
transaction for FDA Determination of Regulatory Review Period 14 Mar, 2024 US10195160
transaction for FDA Determination of Regulatory Review Period 29 Feb, 2024 US10195160
Payment of Maintenance Fee, 4th Year, Large Entity 20 Oct, 2023 US10647649
Second letter to regulating agency to determine regulatory review period 30 Sep, 2023 US10195160
Letter from FDA or Dept of Agriculture re PTE application 28 Sep, 2023 US10195160
Patent Issue Date Used in PTA Calculation 11 Apr, 2023 US11622945
Recordation of Patent Grant Mailed 11 Apr, 2023 US11622945
Patent Issue Date Used in PTA Calculation 04 Apr, 2023 US11617724
Recordation of Patent Grant Mailed 04 Apr, 2023 US11617724
Patent Issue Date Used in PTA Calculation 28 Mar, 2023 US11612573
Recordation of Patent Grant Mailed 28 Mar, 2023 US11612573
Email Notification 23 Mar, 2023 US11622945
Payment of Maintenance Fee, 4th Year, Large Entity 22 Mar, 2023 US10426743
Issue Notification Mailed 22 Mar, 2023 US11622945


Dermavant Sci's Drug Patent Litigations

Dermavant Sci's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 23, 2024, against patent number US11590088. The petitioner Encube Ethicals Pvt. Ltd., challenged the validity of this patent, with Dermavant Sciences GmbH et al. as the respondent. Click below to track the latest information on how companies are challenging Dermavant Sci's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11590088 April, 2024 Pending Dermavant Sciences GmbH et al. Encube Ethicals Pvt. Ltd.


Dermavant Sci Drug Patents' Oppositions Filed in EPO

Dermavant Sci drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 03, 2023, by Sandoz Ag. This opposition was filed on patent number EP16725243A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP16725243A Feb, 2023 SANDOZ AG Granted and Under Opposition


Dermavant Sci's Family Patents

Dermavant Sci drugs have patent protection in a total of 37 countries. It's US patent count contributes only to 28.8% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Dermavant Sci Drug List

Given below is the complete list of Dermavant Sci's drugs and the patents protecting them.


1. Vtama

Vtama is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11590088 Use of Tapinarof for the treatment of chronic plaque psoriasis 13 Nov, 2039
(14 years from now)
Active
US10647649 Process for preparing tapinarof 13 Nov, 2038
(13 years from now)
Active
US11597692 Process for preparing tapinarof 13 Nov, 2038
(13 years from now)
Active
US10195160 Topical pharmaceutical compositions 19 May, 2036
(11 years from now)
Active
US10426743 Topical pharmaceutical compositions 19 May, 2036
(11 years from now)
Active
US11458108 Topical pharmaceutical compositions 19 May, 2036
(11 years from now)
Active
US11612573 Topical pharmaceutical compositions 19 May, 2036
(11 years from now)
Active
US11617724 Topical pharmaceutical compositions 19 May, 2036
(11 years from now)
Active
US11622945 Topical pharmaceutical compositions 19 May, 2036
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vtama's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List